Cost-effectiveness of combination therapy for chronic obstructive pulmonary disease

Canadian Respiratory Journal

Volumn 15, Issue 8, 2008, Pages 437-443

  Chuck, Anderson ^a   Jacobs, Philip ^a   Mayers, Irvin ^a,c   Marciniuk, Darcy ^b  

^a UNIVERSITY OF ALBERTA   (Canada)

^b UNIVERSITY OF SASKATCHEWAN   (Canada)

^c UNIVERSITY OF ALBERTA   (Canada)

Author keywords

COPD; Cost effectiveness analysis; Economics; Lung diseases; Pharmaceuticals

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE PLUS FORMOTEROL; CORTICOSTEROID; FLUTICASONE PROPIONATE PLUS SALMETEROL; FORMOTEROL; LONG ACTING DRUG; OXEZE; SALMETEROL; SALMETEROL XINAFOATE; UNCLASSIFIED DRUG; BRONCHODILATING AGENT; DRUG DERIVATIVE; ETHANOLAMINE DERIVATIVE; SALBUTAMOL;

ADULT; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMBINATION CHEMOTHERAPY; COST EFFECTIVENESS ANALYSIS; DISEASE COURSE; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG MEGADOSE; FEMALE; FORCED EXPIRATORY VOLUME; HEALTH CARE COST; HUMAN; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MORTALITY; PRIORITY JOURNAL; QUALITY OF LIFE; AGED; COST BENEFIT ANALYSIS; COST OF ILLNESS; DRUG COMBINATION; ECONOMICS; HEALTH SURVEY; MIDDLE AGED; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; UNITED STATES;

AGED; ALBUTEROL; BRONCHODILATOR AGENTS; COST OF ILLNESS; COST-BENEFIT ANALYSIS; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; ETHANOLAMINES; FEMALE; FORCED EXPIRATORY VOLUME; HEALTH STATUS INDICATORS; HUMANS; MALE; MARKOV CHAINS; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUALITY-ADJUSTED LIFE YEARS; UNITED STATES;

EID: 60749089756     PISSN: 11982241     EISSN: None     Source Type: Journal    
DOI: 10.1155/2008/257618     Document Type: Article

References (44)

1. Global Initiative for Chronic Obstructive Pulmonary Disease. Global Initiative for Chronic Obstructive lung disease global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease (2006). 2006.
2. Sullivan SD, Ramsey SD, Lee TA. The economic burden of COPD. Chest 2000;117:5S-9S.
3. Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990-2020: Global burden of disease study. Lancet 1997;349:1498-504.
4. Michaud CM, Murray CJ. Burden of disease-implications for future research. JAMA 2001;285:535-9.
5. 2-agonists for maintenance therapy of stable chronic obstructive pulmonary disease: A systematic review. 2002; Technology Report no 27. Ottawa, Canadian Coordinating Office for Health Technology Assessment.
6. World Health Organization and National Heart, Lung and Blood Institute. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Executive Summary: updated 2003. 2003. Bethesda. Global Initiative for Chronic Obstructive Lung Disease.
7. Wouters EF, Postma DS, Fokkens B, et al. Withdrawal of fluticasone propionate from combined salmeterol/fluticasone treatment in patients with COPD causes immediate and sustained disease deterioration: A randomised controlled trial. Thorax 2005;60:480-7.
8. Dal Negro RW, Pomari C, Tognella S, Micheletto C. Salmeterol & fluticasone 50 microg/250 microg bid in combination provides a better long-term control than salmeterol 50 microg bid alone and placebo in COPD patients already treated with theophylline. Pulm Pharmacol Ther 2003;16:241-6.
9. Mahler DA, Wire P, Horstman D, et al. Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2002;166:1084-91.
10. 2-agonists. J All Clin Immunol 2002;110:261-8.
11. O'Donnell DE, Aaron S, Bourbeau J, et al. Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease - 2003. Can Respir J 2003;10(Suppl A):11A-65A.
12. Sin DD, Stafinski T, Ng YC, et al. The impact of chronic obstructive pulmonary disease on work loss in the United States. Crit Care Med 2002;165:704-7.
13. American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1995;152:S77-S121.
14. The Lung Health Study Research Group. Effect of inhaled triamicinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. N Engl J Med 2000;343:1902-9.
15. Celli BR, Cote CG, Marin JM, et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med 2004;350:1005-12.
16. Niwoehner DE, Erbland ML, Deupree RH, et al. Effect of systematic glucocorticoids on exacerbations of chronic obstructive pulmonary disease. N Engl J Med 1999;340:1941-7.
17. Calverley P, Pauwels R, Vestbo J, et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: A randomised controlled trial. Lancet 2003;361:449-56.
18. Calverley PM, Anderson J, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007;356:775-89.
19. Calverley PM, Boonsawat W, Cseke Z, et al. Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. Eur Respir J 2003;22:912-9.
20. Szafranski W, Cukier A, Ramirez A, et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur Respir J 2003;21:74-81.
21. Walters SJ, Brazier JE. Comparison of the minimally important difference for two health state utility measures: EQ-5D and SF-6D. Qual Life Res 2005;14:1523-32.
22. Sin DD, McAlister FA, Man SF, Anthonisen NR. Contemporary management of chronic obstructive pulmonary disease: Scientific review. JAMA 2003;290:2301-12.
23. Paggiaro PL, Dahle R, Bakran I, et al. Multicentre randomised placebo-controlled trial of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease. International COPD study group. Lancet 1998;351:773-80.
24. Oostenbrink JB, Rutten-van Molken MP, Monz BU, Fitzgerald JM. Probabilistic Markov model to assess the cost-effectiveness of bronchodilator therapy in COPD patients in different countries. Value Health 2005;8:32-46.
25. Sin DD, Golmohammadi K, Jacobs P. Cost-effectiveness of inhaled corticosteroids for chronic obstructive pulmonary disease according to disease severity. Am J Med 2004;116:325-31.
26. Ernst P, Gonzalez AV, Brassard P, Suissa S. Inhaled corticosteroid use in chronic obstructive pulmonary disease and the risk of hospitalization for pneumonia. Am J Respir Crit Care Med 2007;176:162-6.
27. Drummond MF, Sculpher MJ, Torrance GW, O'Brien BJ, Stoddart GL. Methods for the Economic Evaluation of Health Care Programmes, 3rd edn. New York: Oxford University Press, 2005.
28. Laupacis A, Feeny D, Detsky AS, Tugwell PX. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. CMAJ 1992;146:473-81.
29. Briggs AH. Handling uncertainty in economic evaluation. In: Drummond MF, McGuire A, eds. Economic Evaluation of Health Care: Merging Theory with Practice. New York: Oxford University Press, 2001.
30. Hirth RA, Chernew ME, Miller E, Fendrick AM, Weissert WG. Willingness to pay for a quality-adjusted life year: In search of a standard. Med Decis Making 2000;20:332-42.
31. Löfdahl C, Ericsson A, Svensson K, Andreaason E. Cost effectiveness of budesonide/formoterol in a single inhaler for COPD compared with each monocomponent used alone. Pharmacoeconomics 2005;23:365-75.
32. Canadian Coordinating Office for Health Technology Assessment (CCOHTA). Guidelines for economic evaluation of pharmaceuticals: Canada, 2nd edn. Ottawa: Canadian Coordinating Office for Health Technology Assessment, 1997.
33. Nelson HS, Weiss ST, Bleecker ER, Yancey SW, Dorinsky PM. The salmeterol multicenter asthma research trial: A comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest 2006;129:15-26.
34. Suissa S, Ernst P, Benayoun S, et al. Low-dose inhaled corticosteroids and the prevention of death from asthma. N Engl J Med 2000;343:332-6.
35. Ernst P, McIvor A, Ducharme FM, et al. Canadian Asthma Guideline Group. Safety and effectiveness of long-acting inhaled beta-agonist bronchodilators when taken with inhaled corticosteroids. Ann Intern Med 2008;145:692-4.
36. Vestbo J, Sorenson T, Lange P, et al. Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: A randomised controlled trial. Lancet 1999;353:1819-23.
37. Burge PS, Calverley PM, Jones PW, et al. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: The ISOLDE trial. BMJ 2000;320:1297-303.
38. Anthonisen NR, Wright EC, Hodgkin JE. Prognosis in chronic obstructive pulmonary disease. Am Rev Respir Dis 1986;133:14-20.
39. Borg S, Ericsson A, Wedzicha J, et al. A computer simulation model of the natural history and economic impact of chronic obstructive pulmonary disease. Value Health 2004;7:153-67.
40. Paterson C, Langan CE, McKaig GA, et al. Assessing patient outcomes in acute exacerbations of chronic bronchitis: The measure your medical outcome profile (MYMOP), medical outcomes study 6-item general health survey (MOS-6A) and EuroQol (EQ-5D). Qual Life Res 2000;9:521-7.
41. Spencer S, Calverley PM, Burge PS, et al. Inhaled salmeterol in obstructive lung disease. Health status deterioration in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001;163:122-8.
42. Alberta Health and Wellness. Alberta Health Care Drug Benefit Plan. (Version current at June 20, 2005).
43. Alberta Health and Wellness. Alberta Health Care Insurance Plan. Schedule of Medical Benefits. 2005. Edmonton, Alberta Health and Wellness.
44. Alberta Health and Wellness. Health Costing in Alberta. Annual Report. 2005. Edmonton, Alberta Health and Wellness.